- Home
- NLSP vs INTS Comparison
NLSP vs INTS Comparison
Compare NLSP & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- INTS
- Stock Information
- Founded
- NLSP 2015
- INTS 2012
- Country
- NLSP Switzerland
- INTS United States
- Employees
- NLSP N/A
- INTS N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- INTS Health Care
- Exchange
- NLSP Nasdaq
- INTS Nasdaq
- Market Cap
- NLSP 12.4M
- INTS 10.9M
- IPO Year
- NLSP 2021
- INTS 2023
- Fundamental
- Price
- NLSP $2.17
- INTS $0.23
- Analyst Decision
- NLSP
- INTS Strong Buy
- Analyst Count
- NLSP 0
- INTS 4
- Target Price
- NLSP N/A
- INTS $4.50
- AVG Volume (30 Days)
- NLSP 193.3K
- INTS 4.0M
- Earning Date
- NLSP 10-17-2025
- INTS 11-12-2025
- Dividend Yield
- NLSP N/A
- INTS N/A
- EPS Growth
- NLSP N/A
- INTS N/A
- EPS
- NLSP N/A
- INTS N/A
- Revenue
- NLSP N/A
- INTS N/A
- Revenue This Year
- NLSP N/A
- INTS N/A
- Revenue Next Year
- NLSP N/A
- INTS N/A
- P/E Ratio
- NLSP N/A
- INTS N/A
- Revenue Growth
- NLSP N/A
- INTS N/A
- 52 Week Low
- NLSP $1.30
- INTS $0.19
- 52 Week High
- NLSP $6.97
- INTS $4.30
- Technical
- Relative Strength Index (RSI)
- NLSP 49.81
- INTS 32.35
- Support Level
- NLSP $1.88
- INTS $0.27
- Resistance Level
- NLSP $2.02
- INTS $0.30
- Average True Range (ATR)
- NLSP 0.13
- INTS 0.02
- MACD
- NLSP -0.01
- INTS -0.01
- Stochastic Oscillator
- NLSP 55.94
- INTS 13.25
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.